Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5a

3 Nov 2015 18:04

RNS Number : 4548E
GoldmanSachs International
03 November 2015
 

Ap24

 

FORM 38.5(a)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

(GS) GOLDMAN SACHS INTERNATIONAL

Company dealt in

PFIZER INC

Class of relevant security to which the dealings being disclosed relate (Note 1)

USD Ordinary

Date of dealing

02 November 2015

 

2. DEALINGS (Note 2)

 

(a) Purchases and sales

 

Total number of relevant securities acquired

Highest price paid (Note 3)

Lowest price paid

(Note 3)

151,557

35.0600 USD

34.7900 USD

 

Total number of securities disposed

Highest price received (Note 3)

Lowest price received

(Note 3)

151,557

34.9830 USD

34.9304 USD

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 4)

Number of relevant securities

(Note 5)

Price per unit

(Note 3)

 

Ap25

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

Put Option / (1.00 : 100.00)

Selling

21 (2,100)

34.0000 USD

AMERICAN

18/12/2015

1.0000 USD

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 3)

Call Option

2,600

0.0000 USD

 

3.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

Date of disclosure

03 November 2015

Contact name

Aadithya Rao and Yiannis Bardis

Telephone number

+44(20) 7051 9046 / +44(20) 7774 7107

Name of offeree/offeror with which connected

Pfizer Inc

Nature of connection (Note 6)

Advisor to Offeror

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEEAXFDESPSFFF
Date   Source Headline
16th May 201411:29 amRNSForm 8.5 (EPT/RI)
16th May 201411:27 amRNSForm 8 (DD) - [Pfizer Inc]
16th May 201411:18 amRNSForm 8.3 - Pfizer Inc
16th May 201411:13 amRNSForm 8.5 (EPT/RI)
16th May 201411:12 amRNSForm 8.5 (EPT/NON-RI)
16th May 201411:00 amRNSRule 2.10 Announcement
16th May 201410:31 amRNSForm 8.3 - Pfizer Inc
16th May 20149:18 amRNSRule 2.10 Announcement
16th May 20147:00 amPRNForm 8.3 - Pfizer Inc.
15th May 20145:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20145:50 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20145:16 pmRNSForm 8 (DD) - [Pfizer Inc]
15th May 20145:14 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
15th May 20143:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:50 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:33 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:32 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
15th May 20143:28 pmBUSForm 8.3 - Pfizer Inc
15th May 20143:26 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
15th May 20143:22 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:10 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:02 pmBUSForm 8.3 - Pfizer Inc.
15th May 20142:50 pmRNSForm 8.3 - [PFIZER INC]
15th May 20142:42 pmBUSForm 8.3 - Pfizer Inc
15th May 20142:29 pmRNSForm 8.3 - [Pfizer Inc]
15th May 20141:55 pmRNSForm 8.5 (EPT/RI) Pfizer Inc. Amendment
15th May 20141:36 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:34 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20141:26 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:24 pmRNSForm 8 (DD) - Pfizer Inc.
15th May 20141:23 pmRNSForm 8.3 - AstraZeneca Plc
15th May 201412:57 pmBUSForm 8.3 - Pfizer Inc.
15th May 201412:39 pmRNSForm 8.3 - [AstraZeneca Plc]
15th May 201412:22 pmRNSForm 8.3 - [Pfizer Inc]
15th May 201412:15 pmRNSForm 8.5 (EPT/NON-RI)
15th May 201412:10 pmRNSForm 8.5 (EPT/RI)
15th May 201412:09 pmBUSForm 8.3 - Pfizer Inc
15th May 201411:55 amRNSForm 8.3 - Pfizer, Inc.
15th May 201411:34 amRNSForm 8 (DD) - [Pfizer Inc]
15th May 201411:32 amRNSForm 8.5 (EPT/RI)
15th May 201411:27 amRNSForm 8.5 (EPT/RI) Pfizer Inc
15th May 201411:04 amRNSForm 8.3 - Pfizer Inc
15th May 201411:00 amRNSForm 8.5 (EPT/RI) - Pfizer
15th May 201411:00 amRNSRule 2.10 Announcement
15th May 20149:39 amRNSRule 2.10 Announcement
14th May 20144:48 pmRNSForm 8.3 - Replacement - Pfizer Inc
14th May 20143:31 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc.
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:23 pmRNSForm 8.3 - AstraZeneca Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.